Yolanda Jerez
Calle Dr. Esquerdo, 46
Madrid, MD 28007, Spain
Madrid, MD 28007, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Antitumor activity of the combination of vinorelbine and gemcitabine in patients with HR + /HER2- advanced breast cancer after CDK4/6 inhibitor.
Journal: Breast cancer research and treatment
Published: July 14, 2025
Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancer.
Journal: Journal of the National Cancer Institute
Published: March 11, 2025
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 06, 2024
TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 20, 2024
Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 09, 2024
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab.
Journal: JAMA oncology
Published: April 27, 2023
Correlation between breast cancer subtypes determined by immunohistochemistry and n-COUNTER PAM50 assay: a real-world study.
Journal: Breast cancer research and treatment
Published: January 25, 2023
How we treat HR-positive, HER2-negative early breast cancer.
Journal: Future oncology (London, England)
Published: January 31, 2022
Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 05, 2021
Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer.
Journal: Future oncology (London, England)
Published: May 28, 2020
Last Updated: 09/26/2026